COVID-19 and treating incarcerated populations for opioid use disorder.  Donelan CJ, Hayes E, Potee RA, Schwartz L, Evans EA.  J Subst Abuse Treat. 2020 Dec 2:108216. doi: 10.1016/j.jsat.2020.108216. Epub ahead of print. PMID: 33288348;…

The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.  Hughto JMW, Peterson L, Perry NS, Donoyan A, Mimiaga MJ, Nelson KM, Pantalone DW.  J Su…

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.  Arunogiri S, Lintzeris N.  J Subst Abuse Treat. 2020 Dec 3:108221. doi: 10.1016/j.jsat.2020.108221. Epub ahead of print. PMID: 33303254; PMCID: PMC7711199…

Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic.  Duncan A, Sanders N, Schiff M, Winkelman TNA. J Subst Abuse Treat. 2021 Feb;121:108161. doi: 10.1016/j.jsat.2020.108161. Epub 2020 Oct 8. PMID: 33371945; PMCID…

Developments in Drug Addiction During COVID-19 - An Austrian Perspective Based on a Clinical Sample.  Fuchs-Leitner I, Yazdi K, Gerstgrasser NW, Rosenleitner J.  Front Psychiatry. 2020 Nov 27;11:602033. doi: 10.3389/fpsyt.2020.602033. PM…

Kanada. Impacts of the COVID-19 Pandemic on Substance Use Treatment Capacity in Canada Key Findings There was a substantial decrease in the availability and capacity of substance use treatment and harm reduction services in the early phase of the…